High-mobility group box family of proteins: Ligand and sensor for innate immunity

Trends in Immunology

Volumn 33, Issue 12, 2012, Pages 633-640

  Yanai, Hideyuki ^a,b   Ban, Tatsuma ^c   Taniguchi, Tadatsugu ^a,b  

^a INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

DAMPs; HMGB proteins; Inflammation; Innate immunity; Nucleic acids; PRRs

Indexed keywords

CALRETICULIN; CD14 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CPG OLIGODEOXYNUCLEOTIDE; DEAD BOX PROTEIN; DOUBLE STRANDED DNA; DOUBLE STRANDED RNA; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP PROTEIN; LIGAND; LIPOPOLYSACCHARIDE; PROTEIN S 100; RETINOIC ACID INDUCIBLE PROTEIN I; SINGLE STRANDED RNA; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; BIOSENSOR; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; PROTEIN EXPRESSION; PROTEIN PROCESSING; REPERFUSION INJURY; REVIEW; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; CYTOKINES; HMGB PROTEINS; HUMANS; IMMUNITY, INNATE; LIGANDS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84869880290     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2012.10.005     Document Type: Review

References (88)

1. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4:469-478.
2. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 2011, 29:139-162.
3. Haraldsen G., et al. Interleukin-33 - cytokine of dual function or novel alarmin?. Trends Immunol. 2009, 30:227-233.
4. Zitvogel L., et al. Decoding cell death signals in inflammation and immunity. Cell 2010, 140:798-804.
5. Kawane K., et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998-1002.
6. Munoz L.E., et al. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 2010, 6:280-289.
7. Napirei M., et al. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 2000, 25:177-181.
8. Bianchi M.E. HMGB1 loves company. J. Leukoc. Biol. 2009, 86:573-576.
9. Rauvala H., Rouhiainen A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr. Mol. Med. 2007, 7:725-734.
10. Sims G.P., et al. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010, 28:367-388.
11. Castiglioni A., et al. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res. 2011, 343:189-199.
12. Muller S., et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 2001, 20:4337-4340.
13. Sessa L., Bianchi M.E. The evolution of high mobility group box (HMGB) chromatin proteins in multicellular animals. Gene 2007, 387:133-140.
14. Calogero S., et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 1999, 22:276-280.
15. Ronfani L., et al. Reduced fertility and spermatogenesis defects in mice lacking chromosomal protein Hmgb2. Development 2001, 128:1265-1273.
16. Vaccari T., et al. Hmg4, a new member of the Hmg1/2 gene family. Genomics 1998, 49:247-252.
17. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005, 5:331-342.
18. Merenmies J., et al. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J. Biol. Chem. 1991, 266:16722-16729.
19. Wang H., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
20. Scaffidi P., et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
21. Deretic V. Autophagy in immunity and cell-autonomous defense against intracellular microbes. Immunol. Rev. 2011, 240:92-104.
22. Huang J., et al. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 2012, 8:275-277.
23. Tang D., et al. Endogenous HMGB1 regulates autophagy. J. Cell. Biol. 2010, 190:881-892.
24. Ellerman J.E., et al. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res. 2007, 13:2836-2848.
25. Bonaldi T., et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003, 22:5551-5560.
26. Tang D., et al. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J. Leukoc. Biol. 2007, 81:741-747.
27. Lamkanfi M., et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 2010, 185:4385-4392.
28. Willingham S.B., et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J. Immunol. 2009, 183:2008-2015.
29. Alleva L.M., et al. Systemic release of high mobility group box 1 protein during severe murine influenza. J. Immunol. 2008, 181:1454-1459.
30. Kazama H., et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008, 29:21-32.
31. Venereau E., et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 2012, 209:1519-1528.
32. Yang H., et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 2012, 18:250-259.
33. Chen G.Y., et al. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323:1722-1725.
34. Palumbo R., et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell. Biol. 2004, 164:441-449.
35. Treutiger C.J., et al. High mobility group 1 B-box mediates activation of human endothelium. J. Intern. Med. 2003, 254:375-385.
36. Fan J., et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J. Immunol. 2007, 178:6573-6580.
37. Andersson U., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 2000, 192:565-570.
38. Degryse B., et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 2001, 152:1197-1206.
39. Abeyama K., et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 2005, 115:1267-1274.
40. Ito T., et al. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1825-1830.
41. Yang D., et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 2007, 81:59-66.
42. Dumitriu I.E., et al. HMGB1: guiding immunity from within. Trends Immunol. 2005, 26:381-387.
43. Jube S., et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012, 72:3290-3301.
44. Tang D., et al. High-mobility group box 1 and cancer. Biochim. Biophys. Acta 2010, 1799:131-140.
45. Pusterla T., et al. High mobility group B2 is secreted by myeloid cells and has mitogenic and chemoattractant activities similar to high mobility group B1. Autoimmunity 2009, 42:308-310.
46. Rouhiainen A., et al. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 2007, 81:49-58.
47. Tsan M.F. Heat shock proteins and high mobility group box 1 protein lack cytokine function. J. Leukoc. Biol. 2011, 89:847-853.
48. Yang H., et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11942-11947.
49. Sha Y., et al. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 2008, 180:2531-2537.
50. Youn J.H., et al. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-a production in human monocytes. J. Immunol. 2008, 180:5067-5074.
51. Tian J., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007, 8:487-496.
52. Urbonaviciute V., et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 2008, 205:3007-3018.
53. Campana L., et al. Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 2009, 86:609-615.
54. Schiraldi M., et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 2012, 209:551-563.
55. Hreggvidsdottir H.S., et al. High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor. Mol. Med. 2012, 18:224-230.
56. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
57. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
58. Yoneyama M., Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol. Rev. 2009, 227:54-65.
59. Ivanov S., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007, 110:1970-1981.
60. Ishikawa H., et al. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
61. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
62. Takaoka A., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505.
63. Unterholzner L., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 2010, 11:997-1004.
64. Zhang Z., et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 2011, 12:959-965.
65. Tamura T., et al. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 2008, 26:535-584.
66. Yanai H., et al. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 2009, 462:99-103.
67. Ishii K.J., et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 2006, 7:40-48.
68. Krieg A.M., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
69. Haas T., et al. The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008, 28:315-323.
70. Matsumoto Y., et al. Bornavirus closely associates and segregates with host chromosomes to ensure persistent intranuclear infection. Cell Host Microbe 2012, 11:492-503.
71. Moisy D., et al. HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication. J. Virol. 2012, 86:9122-9133.
72. Yan N., et al. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat. Immunol. 2010, 11:1005-1013.
73. Honda K., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
74. Chiba S., et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 2012, 13:832-842.
75. Ewald S.E., Barton G.M. Nucleic acid sensing Toll-like receptors in autoimmunity. Curr. Opin. Immunol. 2011, 23:3-9.
76. Kawasaki T., et al. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 2011, 243:61-73.
77. Pisitkun P., et al. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312:1669-1672.
78. Stetson D.B., Medzhitov R. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response. Immunity 2006, 24:93-103.
79. Yanai H., et al. Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11542-11547.
80. Prinz M., et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006, 116:456-464.
81. Segal B.M., et al. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 2000, 164:5683-5688.
82. Li J., et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 2003, 9:37-45.
83. Hu X., et al. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol. Rev. 2008, 226:41-56.
84. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell. Biol. 2001, 2:378-386.
85. Yang H., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:296-301.
86. Lutterloh E.C., et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit. Care 2007, 11:R122.
87. Yang H., Tracey K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 2010, 1799:149-156.
88. Zhu S., et al. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflamm. Allergy Drug Targets 2010, 9:60-72.